Replies to post #1024 on NightHawk Biosciences Inc (NHWK)

[Titan V]

$30 a share would be Q4 BO offer possibility were Heat only doing the NSCLC + Opdivo trial IMO. But they are also closing a phase 2 bladder cancer trial and seem confident about starting phase 3.

BMY recently acquired Flexus for $1.25B. They had one, preclinical, candidate.

The object of Bristol's $1.25 billion deal on Flexus is a drug program that is still in its pre-IND infancy..

We had a data set that suggested it has the potential to be best-in-class, with the ability for a partner to combine it with many other assets. If you look at any company working in oncology, it can potentially increase the value of a whole portfolio of assets. It could be multiplicative and that creates a big valuation," he added.

http://www.fiercebiotech.com/financials/updated-bristol-myers-bags-ido-immunotherapy-1-25b-buyout-of-fledgling-flexus

So BMY is paying based on the drug's potential. I would personally set a price point of $1.25B minimum for Heat. That translates to $64 a share. But Heat has more to offer. Not only can its platform be applied to additional cancer indications but on infectious diseases like HIV as well. I would not be surprised at all to see a 3 figure BO offer for Heat. It's possible when more than one big pharma is interested in the platform. I'm very glad Roche could also benefit from HTBX and not just BMY. However, if Heat can prove the platform's effectiveness in lung and bladder, there could be more companies with big pockets, domestic as well as foreign, that would be interested in acquiring it. For instance...

Takeda earmarks $15bn for US pharmaceutical acquisitions
https://www.ft.com/content/5c8e5c50-79c5-11e6-97ae-647294649b28